News Feature: Broadalumab Efficacy in Axial Spondyloarthritis Broadalumab, an anti-interleukin-17 receptor A monoclonal antibody, is FDA- approved for use in adults with plaque psoriasis; but a recent trial shows it to be effective in patients with axSpA. https://t.co/V0zKbFMgy7 https://t.co/U5CGXUF7Sw